Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00137852
Status:
COMPLETED
Last Update Posted:
2017-09-20
First Post:
2005-08-29
Brief Title:
Cisplatin CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
01-229
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Peter C Enzinger MD
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Pharmacia | INDUSTRY |
| Brigham and Womens Hospital | OTHER |
| Massachusetts General Hospital | OTHER |